Gaa - alpha glucosidase Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 367562

Summary

Enables alpha-1,4-glucosidase activity and carbohydrate binding activity. Involved in glycogen catabolic process. Located in lysosome. Human ortholog(s) of this gene implicated in glycogen storage disease II. Orthologous to human GAA (alpha glucosidase). [provided by Alliance of Genome Resources, Apr 2022]

Gaa Products (1)

mRNA Protein Name
NM_199118.1 NP_954549.1 lysosomal alpha-glucosidase precursor

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence References Source
enables alpha-1,4-glucosidase activity IDA
IDA: Inferred from direct assay
8702598 RGD
enables alpha-1,4-glucosidase activity IMP
IMP: Inferred from mutant phenotype
2193931 RGD
enables carbohydrate binding IDA
IDA: Inferred from direct assay
8702598 RGD
Biological Process GO Annotation Evidence References Source
involved in glycogen catabolic process IDA
IDA: Inferred from direct assay
8710802 RGD
involved in glycogen catabolic process IMP
IMP: Inferred from mutant phenotype
2193931 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

lysosomal alpha-glucosidase

  • acid (Pompe disease, glycogen storage disease type II)

  • acid alpha-glucosidase

  • acid maltase

  • glucosidase, alpha, acid

  • glucosidase, alpha

  • acid (Pompe disease, glycogen storage disease type II)

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-132609 Patisiran sodium 99.09% Unkown
HY-132608 Inotersen sodium 96.44% Unkown
HY-132611 Golodirsen 96.12% Unkown

Clinical Phase

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Phase
HY-132586 Viltolarsen Modulator 95.25% Phase 4
HY-108753 Eteplirsen 98.50% Phase 3
HY-132596 Tivanisiran Inhibitor 97.48% Phase 3
HY-150724 ODN 1018 Agonist 99.28% Phase 2
HY-148100 Emapticap pegol Inhibitor 91.38% Phase 2
HY-132602 Remlarsen Agonist 92.27% Phase 2

Pre-clinical Phase

Bioactive Molecules (18)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-150738 ODN 2088 Antagonist 98.82% Unkown
HY-147217 Bepirovirsen Inhibitor 98.44% Unkown
HY-150750 ODN M362 96.01% Unkown
HY-150736 ODN 20844 Inhibitor 96.14% Unkown
HY-145725A Baliforsen Inhibitor 98.12% Unkown
HY-147412 Ultevursen Modulator 94.24% Unkown
HY-150744 ODN 24888 Inhibitor / Unkown
HY-144124 5-C-heptyl-DNJ Inhibitor / Unkown
HY-150740 ODN 21595 Inhibitor / Unkown
HY-154995 N-4′-(p-Trifluoromethylphenyl)butyl-DAB Inhibitor / Unkown
HY-178200 5-C-phenethyl-DNJ hydrochloride Activator / Unkown
HY-178202 5-C-phenethyl-DNJ Inhibitor / Unkown
HY-183723 GAA-4OH Inhibitor / Unkown
HY-E70183 Lysosomal α-Glucosidase / Unkown
HY-RS05196 GAA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-182209 GAA Trimer phosphoramidite / Unkown
HY-RS17242 Gaa Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23696 Gaa Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gaa NCBI NCBI:2548